Avicanna Reports Q3 2024

Provided By GlobeNewswire

Last update: Nov 14, 2024

9-month revenue of $18.8 million, representing a 75% increase from 2023.

Consolidated Gross Margins of 57%, during Q3 2024.

TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3 2024.